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ABSTRACT 
Carlton, Connor D., Evaluation of lythrine, an alkaloid from Heimia salicifolia, in an 
avian model of anxiety and depression. Master of Science (Biology), May, 2020, Sam 
Houston State University, Huntsville, Texas. 
 
The purpose of this thesis was to evaluate whether an acute exposure to lythrine, a 
naturally occurring alkaloid substance from Heimia salicifolia, has anxiolytic properties 
in a validated avian model of anxiety and depression. Socially raised, five-day-old chicks 
were exposed to an isolation stressor for five minutes after receiving one of five 
treatments. These were: 1) vehicle-treated, 2) clonidine (0.1 mg/kg body weight), and 3) 
lythrine-treated groups at each of the different dosages (0.1 mg/kg, 0.3 mg/kg, 1.0 
mg/kg). All lythrine treatment doses were dissolved in 10% cremaphor, 5% ethanol, and 
85% deionized water. A solution of exclusively 10% cremaphor, 5% ethanol, and 85% 
deionized water served as the vehicle-group. Clonidine was dissolved in saline and 
served as our known anxiolytic positive control comparison. During the exposure to 
isolation stressor, distress vocalizations (DVocs) of the chicks were recorded. Vehicle-
treated animals displayed high rates of DVocs indicative of a panic state and consistent 
with previous findings in this model. Clonidine-treated animals displayed a reduced rate 
of DVocs, indicative of an anti-panic (i.e. anxiolytic) effect. All three lythrine doses 
failed to attenuate panic, as measured by a failure to reduce DVocs in the five-minute 
isolation test. The findings from this study suggest that at the doses tested lythrine does 
not possess anti-panic (i.e. anxiolytic) effects. However, limitations include the low 
dosing as well as housing maintenance issues. For this study, we chose low doses based 
upon lythrine’s limited availability, novelty and limited in vivo testing of the compound, 
and clonidine’s active dosage. Future studies should evaluate both higher and lower doses 
v 
of lythrine in this model to elucidate a dose-response curve while measuring potential 
anxiolytic effects.  Additionally, further evaluation of lythrine’s pharmacokinetics and 
pharmacodynamics is needed. 
KEY WORDS: Heimia, Heimia salicifolia, Salicifolia, Lythraceae, Lythrine, Cryogenine, 
Vertine, Biphenyl quinolizidine lactone, Alkaloid, Aztecs, Anxiety, Panic disorder, 
Avian, Animal model, Psychopharmacology, Behavior, Sam Houston State University, 
Graduate School, Texas  
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Heimia is a genus in the Family Lythraceae that was first described by Johann 
Heinrich Friedrich Link and Friedrich Otto in 1822, when they erected the species 
Heimia salicifolia (Kunth). The genus name Heimia was assigned to honor the German 
physician Ernst Ludwig Heim (1747-1834) and contains four accepted species (Gledhill, 
2008; Malone & Rother, 1994). The species epithet, salicifolia, is derived from Salix 
(willow genus) and folia (leaves), referencing the great resemblance the structure of the 
plant leaves have to the leaves of a willow tree. Common folk names of H. salicifolia 
include Abre-o-sol (Portuguese for “Sun Opener”), Herva de la vida (Portuguese for 
“Herb of Life”), Hierba de San Francisco (Spanish for “herb of St. Francis”), Yerba de 
las ánimas (Spanish for “herb of the spirits”), Shrubby yellowcrest, and Sinicuichi 
(alternate spelling: Sinicuiche) to name a few (Martinez, 1959; Hoehne, 1939; 
Dominguez, et al., 1975).  
Heimia salicifolia is a deciduous shrub varying from 50 to 300 cm in height and 
width. The dark green leaves are decussate and are linear lanceolate to lanceolate in 
shape and 2 - 9.5 cm in length. Heimia salicifolia flowers annually between June and 
September as a yellow 5-7 petal bloom, about 2 cm across, emerging in solitary blooms 
from the leaf axils. The shape is campanulate, with 10-13 stamens and a thin style. The 
fruits of this shrub are dry, rounded four-celled capsules containing very small seeds 
(Link and Otto, 1828). Heimia salicifolia prefers hot, sunny, moist places along streams 
in the high altitudes. Reports indicate wild growth in the southwestern United States, 
including Texas, as well as throughout Mexico, Central and South America. In addition, 
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cultivation has been successful as far north as Baja, California and ranging as far south as 
Argentina (Graham, 1997). 
Gordon Wasson first made the connection between H. salicifolia with Xochipilli, 
the Prince of Flowers (Xochi is from the Nahuatl xochitl or “flower”, while pilli means 
either “Prince” or “child”). This is the Aztec god of psychoactive plants, flowers, spring, 
fertility, maize, love, desire, games, beauty, song and dance (Wasson, 1974). He is also 
referred to as Macuilxochitl, which means "five flowers.” This refers to the five sacred 
and psychoactive entheogens carved onto the Xochipilli statue and its base, which 
currently resides in the Museo Nacional de Antropologia of Mexico. The five entheogens 
the statue depicts are mushrooms (Psilocybe aztecorum), tobacco (Nicotiana tabacum), 
morning glory (Turbina corymbosa), sinicuichi (Heimia salicifolia), and possibly 
cacahuaxochitl (Quararibea funebris). Heimia salicifolia and its medicinal use can be 
traced back to an Aztec herbal manuscript detailing various native plants, their medicinal 
properties and methods used for specific ailments. This manuscript was originally written 
in the Aztec native language of Nahuatl and later translated into Latin in 1552 by Martin 
de la Cruz and Juan Badiano titled Libellus de Medicinalibus Indorum Herbis (Gates, 
2000).  
Leaves of H. salicifolia have been consumed historically as a folk remedy, 
especially in Mexico (Martinez, 1959). Practitioners have employed this remedy for a 
vast majority of ailments including dysentery, inflammation of the uterus, bronchitis and 
other chest illnesses. It has also been used as a diuretic, laxative, antisyphilitic, emetic, 
and a general vulnerary (Martinez, 1959; Blomster, et al., 1964; Douglas, et al., 1964; 
Oliver-Bever, 1972; Lema, et al., 1986; Malone, 1986). Continued modern use seems to 
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be due to these reported medicinal, as well as spiritual properties. Specifically, many 
reports include psychoactive and hallucinogenic experiences after the consumption of a 
decoction of H. salicifolia leaves.  
The traditional method of preparation the Aztecs used was for H. salicifolia 
leaves to be dried until wilted, placed into a cup or bowl of cool water, and set out in the 
sun for at least 24 hours. Unbeknownst to them, this allowed for fermentation to occur. 
Instead practitioners believed that the sun transferred its knowledge and spirit into the 
drink during its fermentation, which is a critical step in the preparation of the tea or 
“elixir of the sun”. One of many reasons for H. salicifolia’s colloquial term “Sun-
Opener” (Bechelli, n.d.). The symbolism of the sun and its energy is a historical theme 
surrounding this plant. Fermentation prior to consuming the tea has long been thought to 
reduce the side effects associated with ingesting the plant material, such as extreme 
muscle soreness, nausea and headache.  
Consumers of the tea have reported mild states of intoxication with trance-like 
states (Diaz, 1979), euphoria, and auditory hallucinations (Schultes & Smith, 1976); 
however, in large doses, there have been reports of visual disturbances and time 
perception disorders (Rother, 1989). The properties of the sinicuichi tea were first 
published in 1897 by J.B. Calderon as possessing a unique physiological action, a 
pleasant drunkenness with objects appearing yellow, and the sounds of bells and human 
voices heard coming from a long distance (Calderon, 1897). Three decades later, Victor 




“strength, energy, and joy awaken the spirit. Objects are very clearly 
 seen in great detail. […] Individuals feel as if walking on a soft carpet. 
 They see a door opened but don’t hear the sound. There is nothing 
 unpleasant, except that objects have a yellow-blue or purple sheen. 
 Users say it is the remedy to secure happiness” (Reko, 1926).  
These descriptions remain very similar to modern personal accounts on the effects 
of sinicuichi tea based upon multiple online resources for psychoactive botanicals, such 
as The Vaults of Erowid (http://www.erowid.org/) and The Lycaeum 
(http://www.lycaeum.org/); two of the most comprehensive and up-to-date psychoactive 
plant databases online today. Although anecdotal evidence, these unusual effects 
described by Calderon, Reko and online forum users are the reasons into the rigor of 
scientific testing and discovery associated with H. salicifolia. These described effects are 
an important aspect in the evaluation of this plant considering its history and common 
cultural practices. However, little scientific research has been conducted on these 
perceived behavioral effects, even though it remains lawful. 
Currently, H. salicifolia nor any of its constituents fall under DEA scheduling for 
controlled substances in the United States. This means all parts of the plant and its 
constituents are legal to cultivate, buy, possess, and distribute (sell, trade or give) without 
a license or prescription.  
Heimia salicifolia products that are available include viable seeds, live plants, 
harvested plant material, and tincture extracts labeled “herbal dietary supplements” 
(http://www.amazon.com/), which do not necessarily comply with Food and Drug 
Administration’s (FDA) safety standards for other medications. Safety testing including 
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contamination prevention measures to ensure harmful pesticides, insecticides, herbicides, 
heavy metals, or residual solvents are not required. No systems, governmental or 
otherwise, are currently in place to confirm any H. salicifolia source’s safety, validity or 
known quantity. This all poses serious public health concerns for those seeking to 
medicate with this substance.  
Numerous alkaloids have been identified in the H. salicifolia plant with the three 
most abundant (in order) being cryogenine, lyfoline, and lythrine (Rother, 1990). They all 
belong to a class of alkaloids known as biphenyl quinolizidine lactones, which are the 
primary biologically active compounds in the Heimia genus. Also included in this class 
are minor alkaloids such as nesodine, heimidine, sinicuichine, dehydrodecodine, 
lythridine, and more, totaling 24 known alkaloids, including six newly isolated ones 
(Kitajima et al, 2018; Kitajima et al, 2019). Interestingly, this group of compounds form 
in the plant at a much larger amount than the biosynthetically simpler group of 
phenylquinolizidinyl esters. The cause of this is unknown. 
The most abundant alkaloid in H. salicifolia, cryogenine (C26H29NO5), has long 
thought to be responsible for the reported psychoactive and hallucinogenic experiences 
associated with this plant (Calderon, 1896; Schultes, 1969; Rother, 1989). Although the 
debate is ongoing, as none of the individual alkaloids of the genus Heimia have been 
classified as a psychotomimetic or psychodysleptic (Malone & Rother, 1994; Rumalla et 
al., 2008). A psychotomimetic or psychodysleptic is a drug or substance that produces 
psychological and behavioral changes resembling those of psychosis; a hallucinogen. 
Cryogenine treatment in animal studies resulted in decrease spontaneous motor activity, 
muscle relaxation, hypothermia, blepharoptosis and ataxia, in addition to being a diuretic 
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(Singh, 2011). Additionally, in rats, cryogenine had anticholinergic, anti-inflammatory, 
antispasmodic, hyperglycemic, hypotensive, sedative, tranquilizer, and vasodilatory 
effects (Malone and Rother, 1994). Cryogenine is also shown to be 2.48 times more 
active than aspirin as a prostaglandin synthetase inhibitor (Lema et al., 1986), which may 
explain much of its anti-inflammatory activity. 
Lythrine (C26H29NO5), the third most abundant alkaloid within the plant (Rother 
1989), is a diastereomer of the purported psychoactive alkaloid cryogenine. Lythrine has 
a (trans)-Z-configuration at C-10 of the quinolizidine ring, while cryogenine has a (cis)-
E-configuration (Figure 1).  
 
Figure 1. Lythrine and cryogenine (vertine) are diastereomers.  
 
 
Lythrine is the trans-isomer, which is lower in enthalpy, and thus is a more stable 
isomer (Bendz, 2013). Lythrine is reported to be a diuretic and to have anti-inflammatory 
effects (United States Patent No. 3,184,446; Weisbach, 1965; Byrne and Malone, 1981), 
and the most potent vasorelaxant alkaloid of H. salicifolia (Guzmán-Hernández et al., 
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2018). As demonstrated in a phenylephrine (Phen) induced model of vasoconstriction 
using isolated and perfused rat mesenteric vascular bed (MVB) preparations with intact 
endothelium, lythrine produced a concentration-dependent vasorelaxation effect. Action 
mechanisms were elucidated via the successful reduction of lythrine-induced vasodilation 
when individually perfusing the in vitro MVB preparations with Nω-nitro-L-arginine-
methyl ester (L-NAME) (an unspecific nitric oxide synthase inhibitor), methylene blue (a 
guanylate cyclase inhibitor), Wortmannin (a phosphatidylinositol 3-kinase inhibitor), and 
atropine (a muscarinic cholinergic receptor antagonist). Additionally, the MVB 
preparations with eliminated endothelial cells significantly reduced the lythrine-induced 
vasodilation. These results suggest that lythrine’s vasorelaxant effect is dependent on the 
release of endothelial nitric oxide synthase (eNOS). The activation of eNOS depends on 
the formation of calcium-calmodulin complex (Su et al., 2014). However, eNOS can also 
be activated by phosphorylation with phosphatidylinositol 3-kinase (PI3K), a calcium-
independent mechanism (Zhang et al., 2014). The PI3K-dependent activation of eNOS is 
also an important mechanism in the vasodilation effect of lythrine, as demonstrated by 
Wortmannin’s strong reduction of lythrine-induced vasodilation. The involvement of 
cyclic guanosine monophosphate (cGMP) in the relaxant and hypotensive effects of 
lythrine was also verified by the complete elimination of lythrine’s vasodilation effects as 
the guanylate cyclase (GC) inhibitor, methylene blue, was introduced. Evidence lythrine 
is mediated through the interaction with cholinergic muscarinic receptors was verified 
through the reduction of lythrine-induced vasodilation with the introduction of the 
muscarinic cholinergic receptor antagonist atropine. In every test, lythrine’s effects were 
reported as similar to the effects of the study’s control drug acetylcholine (ACh) 
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(Guzmán-Hernández et al., 2018). ACh serves as the main neurotransmitter of the 
parasympathetic nervous system with functions of dilating blood vessels, reducing blood 
pressure, and slowing heart rate. These findings demonstrate the close similarity of 
lythrine’s potent vasodilation and hypotensive effects to the established vasodilation and 
hypotensive effects of ACh, which was a critical factor in determining the basis for 
performing this study and formulation of its hypothesis. Additionally, the researchers of 
this study found it logical to evaluate lythrine’s potential anxiolytic effects due to all the 
findings observed in the Guzmán-Hernández study, especially lythrine’s reported potent 
vasodilation properties via the activation of the nitric oxide (NO)/GC pathway. The 
NO/GC pathway initiates and maintains vasodilation through a series of biological events 
resulting in the relaxation of smooth muscle cells lining arteries, veins, and lymphatics 
thus causing a reduction in blood pressure and heart rate. This pathway works when NO, 
formed by vascular eNOS, binds to the heme group of hemoglobin in red blood cells 
(RBC) and to the heme group of the enzyme GC, which is found in vascular smooth 
muscle cells. Once it diffuses into the vascular smooth muscle cells adjacent to the 
endothelium and binds to the GC enzyme, NO activates GC. The GC enzyme then 
catalyzes the dephosphorylation of GTP to cGMP. The cGMP serves as an important 
secondary messenger for signaling smooth muscle relaxation via the phosphorylation, or 
addition of a phosphate group, to the smooth muscle contractile protein of myosin. Once 
myosin is phosphorylated, it relaxes. This relaxation results in the dilation of blood 
vessels originally exposed to NO, and a decrease in blood pressure and heart rate occurs. 
With this information, the scientific backing for the evaluation of lythrine to treat anxiety 
via two common physiological symptoms of anxiety, high blood pressure and increased 
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heart rate, was determined. At 87 percent, accelerated heart rate is the most common 
symptom patients suffering from anxiety and panic attacks self-report (Rapee, Craske, & 
Barlow, 1990). Additionally, according to a systematic review and meta-analysis of 
epidemiological studies, there is a strong association between anxiety and hypertension 
(Yan, et al., 2015). 
The second most abundant alkaloid, lyfoline has no reported effects. 
Important to note is the fact that isolated Heimia alkaloids have been 
experimentally shown to mimic qualitatively and semi-qualitatively the action of the total 
alkaloid extracts of H. salicifolia, especially vasodilation (Schultes, 1969; DeKorne, J. 
2011; Guzmán-Hernández et al., 2018). Therefore, emphasizing further therapeutic and 
medicinal research of isolated lythrine is necessary, as its effects may resemble closely 
the effects of the whole-plant folk decoction of sinicuichi, as well as provide therapeutic 
benefits reported for centuries. 
Additionally, with further testing and understanding of lythrine and the 
therapeutic alkaloids and constituents of H. salicifolia, targeted application of useful 
compounds and respective constituents can be performed. Given this, along with 
lythrine’s diuretic, anti-inflammatory, sedative, anti-hypertensive, and vasorelaxant 
effects, an investigation of this individual compound’s potential psychological benefits, 






According to the American Psychiatric Association’s (APA) Diagnostic and 
Statistical Manual of Mental Disorders, Fifth Edition (DSM-V), anxiety disorders include 
conditions that share features of excessive fear and anxiety and related behavioral 
disturbances. Anxiety is described as the anticipation of future threat. More relatedly to 
this project’s model, panic attacks are an abrupt surge of intense fear or intense 
discomfort that reaches a peak within minutes, and during which time four or more of a 
list of 13 physical and cognitive symptoms occur. These symptoms include palpations, 
pounding heart or accelerated heart rate; sweating; trembling or shaking; sensations of 
shortness of breath or smothering; feelings of choking; chest pain or discomfort; nausea 
or abdominal distress; feeling dizzy, unsteady, light-headed, or faint; chills or heat 
sensations; paresthesia (numbness or tingling sensations); derealization (feelings of 
unreality) or depersonalization (being detached from one-self); fear of losing control or 
“going crazy”; and fear of dying (APA, 2013, pp. 189, 208-217). 
According to facts and statistics presented by the Anxiety and Depression 
Association of America (ADAA), anxiety disorders are the most common mental illness 
in the U.S., affecting 40 million adults in the United States age 18 and older, or 18.1% of 
the population every year. Additionally, anxiety disorders affect 25.1% of children 
between 13 and 18 years old. Untreated children with anxiety disorders are at a higher 
risk of performing poorly in school, absence at important social experiences, and 
engaging in substance abuse. Anxiety disorders are highly treatable, yet only 36.9% of 
those suffering receive treatment. Many people with an anxiety disorder have 
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comorbidity, commonly depression or physical illness, which can make their symptoms 
worse and recovery more difficult. People with an anxiety disorder are three to five times 
more likely to go to the doctor and six times more likely to be hospitalized for 
psychological disorders than those who do not suffer from anxiety disorders.  
Generalized Anxiety Disorder (GAD) affects 6.8 million adults, or 3.1 percent of 
the United States’ population, yet only 43.2 percent are receiving treatment. Panic 
Disorder (PD) affects 6 million adults, or 2.7 percent of the United States’ population 
(ADAA, 2018). This affects women twice as often as men on paper, although these 
numbers are based on reported individuals. The number for men may be higher as they 
are less likely to report and seeking treatment is less prevalent in this group. Additionally, 
confusing panic attacks with heart attacks are a concern, as they manifest similarly (i.e. 
chest pains).  
In 2013, the annual cost of anxiety disorders in the United States was $48.72 
billion, which is a significant portion of the United States healthcare resources 
(Shirneshan, 2013). However, these costs can be split between the psychological 
treatment of anxiety and the physiological or somaticized symptoms resulting from 
anxiety. According to The Economic Burden of Anxiety Disorders, a study 
commissioned by the ADAA and based on data gathered by the association and published 
in the Journal of Clinical Psychiatry, anxiety treatments cost almost one third of the $148 
billion total mental health bill per year for the U.S. and more than $22.84 billion of those 
costs are associated with the repeated use of healthcare services due to the somatization 
of anxiety, which is the conversion of the anxious mental state into physical symptoms, 
such as severe stomach aches, chest pains, and migraines. 
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There is a bifurcation of the common treatments for anxiety disorders. One 
treatment option is non-pharmacological, which includes therapies such as Cognitive 
Behavioral Therapy (CBT), cognitive restructuring, interoceptive and structured 
exposure, Ost’s applied relaxation, and breathing retraining. The goals of these 
techniques include gaining skills to control physiological activity. They seek to 
restructure one’s thoughts via change in behavior – calming the mind through 
physiological actions. In some cases, such as Ost’s applied relaxation and breathing 
retraining, this includes reducing heart rate by controlling respiration rate. 
The second treatment option is the use of pharmaceutical drugs, such as 
barbiturates and benzodiazepines. Barbiturates were the original class of anxiolytic drugs 
used largely in the 1960s and 1970s as a treatment for anxiety, insomnia, and seizure 
disorders. Barbiturates are known as central nervous system (CNS) depressants. They 
enhance the action of gamma-aminobutyric acid (GABA), a neurotransmitter that inhibits 
the activity of nerve cells in the brain. Apart from a few specific indications, they are 
rarely prescribed for anxiety anymore, having been superseded by benzodiazepines. In 
the 1970s, these barbiturates were given the nickname “downers” due to their strong 
suppressive effect on the CNS, causing many people to die after taking high doses. 
Barbiturates are also extremely addictive. Together, these factors are why they are rarely 
prescribed today.  
Benzodiazepines, such as alprazolam, clonazepam, diazepam, and lorazepam, 
reduce cellular activity in the amygdala – a small, paired structure of the brain located in 
the medial temporal lobe, just anterior to the hippocampus and is primarily associated 
with autonomic responses of emotional processes, especially fear. It has been 
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demonstrated to be hyperactive in patients experiencing anxiety symptomology 
(Bremner, 2004; Damsa, Kosel, & Moussally, 2009; Kent & Rauch, 2003; Rauch, Shin, 
& Wright, 2003). Benzodiazepines are agonists of the gamma-aminobutyric acid-alpha 
(GABA-A) receptor, and when bound, causes an allosteric modulation to occur in the 
receptor resulting in the opening of chloride-ion channels. This allosteric modulation is a 
structural change of the GABA-A receptor, thus allowing increased chloride-ion 
migration into the motor neurons and an increase in GABA-A receptor activity. 
Ultimately, this results in cellular hyperpolarization, or the flooding of negative ions into 
the neuron, causing the inhibition of the ability of an action potential to fire, as an action 
potential must reach a firing rate at a positively charged threshold. The amygdala is 
densely packed with GABA-A receptors and their sustained activation by 
benzodiazepines decreases amygdala activity via the mechanisms described above and 
provides anxiety symptom relief (Shin & Liberzon, 2009). The primary shortcoming of 
benzodiazepines is their high risk for abuse and dependence. Long-term use is not 
advised or recommended, as withdrawal reactions will occur when discontinuing use. 
Common side effects for benzodiazepines are drowsiness, sleepiness, or dizziness. 
Additionally, unusual sleep behaviors and even anterograde amnesia may occur. 
Alternatively, clonidine, an FDA-approved anxiolytic, produces its anxiolytic 
effects through a different mechanism. Clonidine belongs to a drug class called alpha-
agonist hypotensive agents. Clonidine is an agonist at the presynaptic noradrenaline 
alpha-2 autoreceptor. When introduced to the system, it binds to the alpha-2 autoreceptor, 
which is coupled to an inhibitory G-protein and located in the noradrenaline pre-synaptic 
neuron. When bound, the inhibitory G-protein is activated, thus inactivating the enzyme 
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adenylate cyclase. Consequently, this inhibits the production of the enzymes cyclic 
adenosine monophosphate (cAMP) and protein kinase A (PKA, also known as cAMP-
dependent protein kinase). A derivative of adenosine triphosphate (ATP), cAMP is used 
for intracellular signal transduction, such as transferring into cells the effects of hormones 
like adrenaline, which cannot pass through the plasma membrane. The reduction of 
cAMP and PKA production leads to the reduction of calcium current influxes into the 
neuron. Ultimately, causing the neuron to restore its polarization state and stop the 
release of noradrenaline to the synaptic cleft. The result is the reduction of sympathetic 
outflow from the CNS and decreases of noradrenaline activity in the brainstem and on 
cardiac muscle, thus decreasing heart rate and blood pressure. It is this reduction in these 
physiological measures, blood pressure and heart rate, that result in clonidine’s anxiolytic 
effect. Side effects of clonidine are also numerous and undesirable and include, for 
example, hypotension and tachycardia (Drugs.com, 2019). 
Because of the societal impact of anxiety disorders combined with the side effects 
or consequences of current anxiolytic pharmacotherapies, the need to identify novel 
therapeutics for these disorders is vital. Exploring natural products may be a promising 
avenue. 
Natural products are beginning to gain more recognition in mainstream science as 
possible remedies for psychological ailments such as anxiety, post-traumatic stress 
disorder (PTSD) and various addictions. For example, the Multidisciplinary Association 
for Psychedelic Studies (MAPS) has been testing entheogens marijuana, ayahuasca, 
ibogaine, peyote, kratom, mescaline, and psilocybin to treat a variety of mental disorders, 
and various behavioral and substance addictions. Entheogens are psychoactive plants or 
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chemical substances that induce alterations in perception, mood, consciousness, 
cognition, or behavior, especially in a spiritual context. In a similar vein of focusing on 
natural products as potential psychological therapeutics, including those derived from a 
psychedelic source, this study attempted to add to that body of research. To date, no study 
has examined H. salicifolia, and specifically lythrine’s potential therapeutic value for 
psychological disorders. Thus, the current study aims to evaluate the potential anxiolytic 
(i.e. anti-panic) effects of lythrine in a well validated avian model of anxiety and 
depression. 
As mentioned previously, Guzmán-Hernández and colleagues reported lythrine’s 
potent vasodilation properties with physiological effects similar to ACh, such as 
reduction in blood pressure and heart rate. These are similar physiological responses to 







The objective of this project was to evaluate lythrine for potential anxiolytic 
effects. Given lythrine’s vasodilation and resulting blood pressure and heart rate 
reduction, it was reasonable to assume that it may have anxiolytic effects similar to 
clonidine. 
The researcher hypothesized (H1) one, or more, of the doses of lythrine would 
produce anxiolytic effects as measured by a reduction in DVoc rates during the five-
minute isolation period, similar to that of clonidine.  
The null hypothesis (H0) is accepted if no statistically significant differences (i.e. 
reduction in DVoc rates) are observed between lythrine-treated groups and vehicle-
treated group. Additionally, in order to compare lythrine to a known anxiolytic, a 




Materials and Methods 
Chick Anxiety-Depression Model 
Although the aim of this study is focused on exclusively identifying potential 
anxiolytic effects of lythrine, a description of the entire model and its utility follows.  
The chick anxiety-depression model is a dual pharmacological screening assay in 
which both anxiety and depression present sequentially over a 90-minute isolation period. 
This paradigm utilizes socially raised domestic fowl chicks (gallus gallus domesticus), 
aged 4-6 days post hatch. Exposure to isolation stress produces the behavioral measure 
known as distress vocalizations (DVocs), which are recorded via custom designed 
software. The DVoc rate during the first five minutes of isolation are high and models a 
panic state (i.e. anxiety), then declines over the next 20-30 minutes to about half of their 
initial rate and remain stable for the remainder of isolation. The last 60 minutes of 
isolation models behavioral despair (i.e. depression). These two phases are 
pharmacologically dissociable in that anxiolytics reduce DVoc rates during the initial 
anxiety phase and antidepressants increase DVoc rates in the depression phase (i.e. 
attenuation of behavioral despair). 
Even though rodent-based models seemingly remain the preferred models for 
pharmacological screening of anxiolytic compounds, with the open-field and elevated 
plus maze tests being the most commonly used to screen anxiolytics, the chick model has 
accurately screened all current FDA-approved drugs for the treatment of anxiety, 
specifically panic disorder, and depression (Sufka et al., 2009; Warnick, Wicks, and 
Sufka, 2006). It has accurately screened several clinically efficacious anxiolytics, such as 
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the benzodiazepine chlordiazepoxide, and noradrenaline alpha-2 agonist clonidine. 
Additionally, the model has accurately screened clinically relevant antidepressants for 
anxiolytic effects. For example, high doses of antidepressants, such as the tricyclic 
antidepressant imipramine and the tetracyclic antidepressant maprotiline, produce 
anxiolytic effects in the clinical setting, as well as in the model (Sufka et al., 2006; 
Warnick et al., 2008). Combined, these findings support evidence for the high predictive 
validity for this avian model. Meaning the model can detect the anxiolytic effects of a 
wide range of compounds. The high predictive validity of the model reduces the 
vulnerability to false positives, where a drug shows efficacy in the animal model but fails 
in clinical trials, and/or false negatives, where a drug screens ineffective in the model but 
would have benefited individuals with ailment. Models with less predictive validity are 
more prone to false positives, which push ineffective drugs into Phase I and II of clinical 
trials exposing human subjects to potentially harmful compounds and using valuable 
investment resources by costing millions of dollars. Additionally, models prone to false 
negatives prevent effective compounds from clinical use, and thus fail to provide 
effective treatment for those suffering. This also effects corporate shareholder 
profitability. 
A major concern regarding the rodent models listed above is their ability to meet 
the National Institute of Health’s (NIH) and United Kingdom’s policy of Reduction, 
Refinement, and Replacement. Compared to rodent models, this avian model reduces the 
number of purpose-bred research animals as male chicks are a by-product of the 
commercial egg-laying industry, which are otherwise discarded at hatch. The male chicks 
used in drug screening adds no purpose-bred animals, and even decreases the necessity of 
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purpose-bred animals for research. The methodology of this model also meets the second 
“R” of refinement by minimizing the stress-provoking stimuli to a single 90-minute test 
session. The current study further minimized the stress-provoking stimuli to a 5-minute 
test session. Finally, the model also replaces the standard rodent-based models of anxiety 
and depression with a lower phylogenetic, and perhaps, less sentient species according to 
the NIH hierarchy of sentient species (National Institute of Health, 2020). Through the 
development and validation of the avian model described above, many of these concerns 
have been addressed. 
This chick paradigm provides a more clinically relevant, non-rodent-based model 
of psychological syndromes and is useful as a dual drug screening for both anxiolytic and 
antidepressant compounds. As mentioned above, evidence of the model’s strong 
predictive validity has been demonstrated by its ability to accurately screen all current 
FDA-approved drugs for the treatment of anxiety (i.e. panic disorder) and depression 
(Sufka et al., 2009; Warnick, Wicks, and Sufka, 2006). Furthermore, given the high 
comorbidity of anxiety and depressive disorders, this chick anxiety-depression model 
more closely resembles the clinical presentation of these disorders, as it can simulate both 
an anxiety phase and depression phase over a 90-minute test period. 
 
Methods 
Cockerels are received into the laboratory on hatch day and housed in 34 x 57 x 
40 cm cages with 12 chicks per cage. Food and water are available ad libitium via gravity 
feeders (Figure 2). Daily maintenance that entails the replacement of tray liners and 
filling food and water gravity feeders is conducted during the hour that precedes the 
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animal’s dark cycle. Lights are operated on a 12:12 light-dark cycle. Supplemental 
heating sources are provided to maintain appropriate housing temperatures in the range of 
34-35oC. 
 
Figure 2. Chick housing. 34 x 57 x 40 cm cages. Food and water are available ad libitium 
via gravity feeders. 
 
A six-unit testing apparatus containing Plexiglas chambers (25 x 25 x 22 cm) 
surrounded by sound attenuating media is used to record separation-induced vocalizations 
aimed at modeling anxiety (0-5 minutes of social separation) and depression (30-90 
minutes of social separation) patterns of responses (Figures 3 & 4). Each unit is lined 
with acoustical fiber media, illuminated by a 25-Watt light bulb, and ventilated by an 8-
cm-diameter rotary fan (Model FP-108AX S1, Commonwealth Industrial Corp., Taipei, 
Taiwan). Miniature video cameras (Model PC60XP, SuperCircuits, Inc., Liberty Hill, 
Texas, USA) mounted in the sound-attenuating enclosures at floor level and routed 
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through a multiplexor (Model PC47MC, SuperCircuits, Inc.) provided televised display 
of the chicks for behavioral observation (Figure 5). To record DVocs, microphones 
[Radio Shack Omnidirectional Model 33-3013 (modified for AC current)] are mounted at 
the top of the Plexiglas chamber. These vocalizations are routed to a computer equipped 
with custom designed software for data collection. 
 
 
Figure 3. Six-unit testing apparatus. Used to record separation-induced vocalizations 
aimed at modeling anxiety (0-5 minutes of social separation) and depression (30-90 





Figure 4. Plexiglas chamber. Surrounded by sound attenuating media with a microphone 









Test compounds were dissolved in 10% cremaphor, 5% ethanol, and 85% 
deionized water. Isolated conditions included a vehicle-treated group, a clonidine-treated 
group (0.10 mg/kg) and 0.1, 0.3, and 1.0 mg/kg lythrine-treated groups. Lythrine was 
sourced from Cayman Chemical at 95+% purity (CAS 5386-10-2). 
Squads of six chicks were taken from their home cage (labeled A-I) and placed 
within a lidded plastic transport container. To track subject assignment to various 
treatment conditions, chicks were marked using colored felt pens. Body weight was 
recorded for each chick to determine volume of drug administration and to identify 
outliers (i.e. low body weight (<30g), which may signify unhealthy development). Drugs 
were administered via intraperitoneal (IP) injection. Injection-to-test interval was 15 
minutes. This is the time from which the chick was injected to the time the chick was 
placed into the testing apparatus, beginning the evaluation. This time was based on the 
standard practice of the earlier research in this lab, and the limited body of previous 
studies on lythrine and its pharmacokinetics. Chicks were group transported inside the 
lidded container to an adjacent testing room. Each chick was placed into an individual 
testing unit. Doors for the testing chamber were then closed and secured. The program for 
recording vocalizations was started and allowed to run for 6 minutes to record behavior in 
the anxiety-phase only. The extra minute was run for any possibility of computer-
automated timing errors. The original 90-minute test was abbreviated to minimize the 
exposure of the subjects to excess stress, as there is no reasonable expectation of 
antidepressant effects by lythrine according to previous literature. Following the 
completion of the test session, chicks were removed from the testing apparatus and 
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returned to their home cage. Records of the electronic files from the data collection 
program recording vocalizations were stored on the hard drive and backed up on a flash 
drive for data analysis. The dependent measure of distress vocalizations was recorded as 
a rate function (i.e. DVoc/min). For statistical analysis, data was converted into a 
DVoc/5min rate function. Data was analyzed via IBM SPSS Statistics v22 software 
package performing a univariate analysis using treatment factor one-way ANOVA, and 
Dunnett’s test for post-hoc analysis. Each treatment group included 18 chicks, totaling 
90. This sample size was determined based on prior research in this chick model to yield 
an adequate statistical power of 0.80 or above. An anxiolytic effect is defined as a 
significant reduction in average DVoc rates over the five-minute isolation period, 
compared to the vehicle-treated animals. The miniature cameras located within each 
isolation unit allowed for the observation of any sedative (i.e. lethargy) effects produced 
by test articles.  
Animals were observed for potential sedative effects which would have 
confounded DVoc rates. Data sheets were kept next to the laptop. Mild sedative effects 
(i.e. lethargy) were observed in approximately 25% of clonidine animals, however, no 
sedation was observed in any of the lythrine-treated groups at any of the doses test, nor 





No significant effect of lythrine on DVocs was observed (Figure 6). The pattern 
of DVocs in vehicle-treated isolated chicks is consistent with previous findings from this 
laboratory. Vehicle-treated isolated birds displayed high rates of distress calls during the 
five minutes of isolation (i.e. anxiety phase). A one-way ANOVA of the isolated groups 
during anxiety phase of the model (0-5 min) showed a significant main effect for 
treatment (F4,89 = 10.111, p = 0.000), ηp
2 = 0.322, observed power = 1.000. Dunnett’s 
post-hoc analysis revealed a significant effect for clonidine (i.e. anxiolytic effect) and 
failed to reveal significant differences between the vehicle group and any of the three 
lythrine groups (i.e. lythrine failed to produce anxiolytic effects). 
 
Figure 6. The effects of clonidine and lythrine on isolated-induced distress vocalizations 
(DVocs). Values represent mean (SEM) DVoc for a 5-min isolation period as a function 
of the five treatment groups. *Indicates significant decrease in DVoc compared with 








The goal of this project was to evaluate the naturally occurring alkaloid of H. 
salicifolia, lythrine, for potential anxiolytic effects in the chick anxiety-depression model. 
This model is well-validated and possesses high predictive validity as all FDA-approved 
anti-panic medications have been positively screened in the model (Warnick, Wicks and 
Sufka, 2006).  
Due to the high predictive validity of this model, lythrine’s vasorelaxant 
properties and, more specifically, its resulting reduction of heart rate and blood pressure 
(Guzmán-Hernández et al., 2018), it was hypothesized that one or more of the lythrine 
doses would demonstrate anti-panic effects as measured by a reduction in distress 
vocalizations. Lythrine’s effect on heart rate and blood pressure reduction is similar to 
that of the known anxiolytic clonidine. As mentioned previously, clonidine reduces heart 
rate and blood pressure by its reduction of noradrenergic activity on heart muscle, and 
therefore, used specifically in the treatment of panic disorders. As such, clonidine was 
chosen as the positive control compound. 
In congruence with previous findings of this lab, the vehicle-treated animals 
displayed high rates of distress calls during the five-minute isolation period (i.e. anxiety 
phase), indicative of the animals in a panic state. As expected, clonidine-treated animals 
attenuated DVoc rates, indicative of an anti-panic (i.e. anxiolytic) effect. However, none 
of the three doses of lythrine (0.1, 0.3, 1.0 mg/kg) produced a significant attenuation of 
panic (i.e. did not produce anxiolytic effects), as measured by change in DVocs compared 
to vehicle treated (Figure 6). The findings from this study suggest, at the doses tested, 
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lythrine does not produce anti-panic (i.e. anxiolytic) effects. Therefore, the hypothesis is 
rejected, and the null must not be rejected.  
The lack of statistically significant results for lythrine may be due to the poor 
absorption of lythrine when injected IP. The study referenced earlier by Guzmán-
Hernández et al. produced significant results indicating lythrine’s potent vasodilation 
effects via intravenous (IV) administration. Although a very common route of 
administration for this model and standard in pre-clinical trials, IP injection depends on 
the absorption of numerous cell layers, thus slowing the substance’s absorption rate 
compared to IV. Given the factors of age and size of the subjects, IV was not considered 
in this study, as the difficulty of locating and correctly injecting blood vessels of 4-day-
old chicks may have been extremely challenging and an additional stressor on the animal, 
thus confounding stress manipulation. Intramuscular (IM) injection could be an effective 
alternative for future studies, as this route of administration is also common and may 
allow for better absorption into the blood stream compared to IP injection. 
Limitations of the current study include dosage potency, housing maintenance 
issues, and the lack of research involving lythrine’s pharmacokinetics, especially in avian 
models. Originally, 25 mg of lythrine were ordered and drug was diluted according to 
company specifications to test 10 mg/kg, 3 mg/kg, and 1 mg/kg. These doses were 
chosen based on previous research in rodents with lythrine and its diastereomer 
cryogenine wherein higher doses of these compounds (100 mg/kg for lythrine; 68 mg/kg 
for cryogenine) with IP administration resulted in death (Kaplan & Malone, 1966; 
Robichaud et al., 1964), and 5-15 mg/kg of lythrine administered orally to rats was active 
as a diuretic (Weisbach, 1965). The vendor of lythrine recommended to dissolve with 
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DMSO at a ratio of 20mg lythrine:1mL DMSO. In order to perform serial dilution for 
purpose of injection, saline was added to attain test doses. However, data included with 
the drug failed to describe lythrine’s hydrophobic properties. Thus, after adding saline to 
the DMSO/lythrine solution to perform injections, a precipitate formed, rendering the 
solution unusable. After consultation with the vendor, a significantly reduced volume of 
lythrine was acquired (6.0 mg). The highest dosages available were the ones used in this 
study (1 mg/kg, 0.3 mg/kg, and 0.1 mg/kg). The resulting reduction in doses is potentially 
an additional factor contributing to the null results. 
Additionally, maintenance of the animals on the final day of housing in their 
vivarium housing units was absent. While unconfirmed, the lack of resources (i.e. food 
and water) may have influenced the bioavailability (i.e. absorption) of the drug, and 
behavioral stress response (i.e. DVocs) once isolated. Evidence for this possibility can be 
seen in clonidine’s effects. Compared to previous studies in this model, clonidine showed 
exaggerated anxiolytic effects and atypical sedative effects at the dose tested. The lack of 
previous research regarding lythrine’s pharmacokinetic properties in any model is a 
limitation, especially in conjunction with the accidental lack of resources provided to the 
chicks on the final day of housing. Without having a better understanding of lythrine’s 
pharmacokinetics, we are unable to speculate whether lythrine was metabolized at an 
altered rate, thus affecting the inject-to-test interval and, more importantly, the DVoc rate 
of each treatment group. However, data suggests the lack of resources had an effect, as 
the clonidine group showed more sedation and fewer DVocs compared to previous 
studies in the lab. In clinical settings, clonidine is recommended to take on a full stomach.  
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Lythrine-treated groups at all doses tested increased in DVocs compared to the 
vehicle-treated group. Although not statistically significant, lythrine did produce a dose 
response, thus these increase in DVocs may suggest that the doses tested were too high. 
However, this increase could also be caused by the stress factor of experiencing 
dehydration and/or empty stomach due to the lack of housing resources. Alternatively, 
this may indicate an angiogenic property of lythrine, however, more testing is necessary 
to make that claim. 
Regarding these findings the researcher suggests multiple future studies are 
necessary. Firstly, testing both higher and lower dosages of lythrine concentrations to 
elucidate a dose-response curve for potential anxiolytic effects. This could further explore 
if lythrine and biphenyl quinolizidine lactones as a group are potentially a new class of 
anxiolytics – a drug class at an impasse for new discoveries for quite some time (Griebel 
and Holmes, 2013).  
Additionally, the further evaluation of the pharmacodynamic and pharmacokinetic 
properties of lythrine, both in vivo and in vitro settings are necessary in order to more 
comprehensively understand how this compound may work in clinical settings. These 
studies are needed to further elucidate the mechanisms and pathways by which lythrine 
works in the body, including the affinity, efficacy, and potency, as well as the time course 
of lythrine’s absorption, distribution, metabolism and extraction. A method beneficial for 
further understanding the compound’s pharmacokinetics of the circulatory system, and 
help injection-to-test interval timing, would be to test the blood concentration of lythrine 
at various time points from 0 to 60 minutes after various methods of administration. The 
objective being the determination of how quickly the compound circulates throughout the 
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subject’s bloodstream, when concentration peaks, and how long complete metabolization 
occurs. 
Finally, the researcher suggests the evaluation of a traditionally made whole plant 
extract of H. salicifolia using this chick model to test anxiety effects via gavage 
administration of the sinicuichi tea decoction. The substance should be chemically 
analyzed to ensure the inclusion of all major alkaloids mentioned. This evaluation would 
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Damsa, C., Kosel, M., & Moussally, J. (2009). Current status of brain imaging in anxiety 




DeKorne, J. (2011). Psychedelic shamanism: The cultivation, preparation, and shamanic 
use of psychotropic plants. Berkeley, Calif: North Atlantic Books. 
Diagnostic and Statistical Manual of Mental Disorders: DSM-5. (2013). Arlington, VA: 
American Psychiatric Association. 
Diaz, J. L. (1979). Ethnopharmacology and Taxonomy of Mexican Psychodysleptic 
Plants. Journal of Psychedelic Drugs 11 
Dominguez, X. A., Marroquín, J., & Quintero, B. S., Vargas, S. B. (1975). Two new 
quinolizidine alkaloids from Heimia salicifolia. Phytochemistry,14(8), 1883-1884. 
doi:10.1016/0031-9422(75)85325-8 
Douglas B., Kirkpatrick J. L., Raffauf R. F., Ribeiro O., Weisbach J. A., (1964). 
Problems in chemotaxonomy. II. The major alkaloids of the genus Heimia. 
Lloydia 27:25-31. 
Facts & Statistics | Anxiety and Depression Association of America, ADAA. (2019).
 Retrieved 11 December 2019, from https://adaa.org/about-adaa/press-room/facts
 statistics 
Gates, W. (2000). An Aztec herbal: The classic codex of 1552. Mineola, NY: Dover 
Publications. 
Gledhill, D. (2008). The Names of Plants. Cambridge: Cambridge University Press. 
Graham, S. “Type Species: Heimia Salicifolia.” Archive. Kent University, 1997. 
http://web.archive.org/web/19970624061507/http://simon.kent.edu/Biology/Resea
rch/Shirley_Graham/Genera/heimia.html 
Griebel, G. and Holmes, A. (2013). 50 years of hurdles and hope in anxiolytic drug
 discovery. Nature Reviews Drug Discovery, 12(9), pp.667-687. 
33 
 
Guzmán-Hernández, E. A., Segura-Cobos, D., Amato, D., Avila-Acevedo, J. G., & 
Vazquez-Cruz, B. (2018). Evaluation of antihypertensive and vasorelaxant effects 
of Heimia salicifolia (family: Lythraceae). African Journal of Pharmacy and 
Pharmacology,12(3), 41-51. doi:10.5897/ajpp2017.4860 
Hoehne, F. C. (1978). Plantas e substâncias vegetais tóxicas e medicinais. São Paulo: 
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 3D Photogrammetry Modeling of Wound Trauma 
 Micro-CT Application of Wound Trauma 
 
Current interests 
  Neuropsychopharmacology 
 Behavioral Pharmacology 
 Pharmacodynamics and Pharmacokinetics of psychotropics 
 Cannabis cultivation efficiency techniques 
 Medicinal Agriculture 




Texas Research Institute for Environmental Studies (TRIES), Huntsville, Texas 
 Directors: Justin Williams, Ph.D., and William Godwin, Ph.D. 
 Survey of the Long Leaf Pine in the Big Thicket National Preserve 
 June 2019 – September 2019 
 
Southeast Texas Applied Forensics Science Facility, Huntsville, Texas 
 Directors: Dr. Joan Bytheway and Dr. Patrick Lewis 
 Bone marrow biopsies and 3D Photogrammetry of cadavers 




Sam Houston State University, Department of Biological Sciences, Huntsville, Texas 
  Committee: Justin Williams, Patrick Lewis, James Harper, Stephen White 
M.S. Thesis: Evaluation of lythrine, an alkaloid from Heimia salicifolia, in the 
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chick model of anxiety and depression 
May 2018 - Current 
 
Sam Houston State University, Department of Biological Sciences, Huntsville, Texas 
 Principal Investigator: Dr. Patrick Lewis 
Evaluating the decomposition process of machete wounds on human cadavers 
using 3D Photogrammetry technology  
May 2016 – April 2017 
  
Sam Houston State University, Department of Biological Sciences, Huntsville, Texas 
  Principal Investigator: Dr. Patrick Lewis 
Understanding the microbiome of the bone marrow in decomposing human 
cadavers 
May 2016 – October 2016 
 
University of Florida, Department of Food Science and Human Nutrition, Gainesville, FL 
  Principal Investigator: Dr. James Collins 
Determining if iron transporter DMT1 can transport copper through intestines 
January – May 2016 
  
University of Florida, College of Veterinary Medicine, Small Animal Hospital, 
Gainesville, FL 
  Principal Investigator: Dr. Stanley Kim 
Evaluating knee kinematics in dogs using 3D bone modeling and X-ray imaging 
for shape-matching using JointTrack 
January – April 2014 
 
POSTER PRESENTATIONS 
   
American Association of Physical Anthropologist (AAPA) 
 April 2017 
 
Texas Association of Biological Anthropologists (TABA) 




Carlton, C. D., Mitchell, S., & Lewis, P. (2018). Preliminary application of Structure 
from Motion and GIS to document decomposition and taphonomic processes. Forensic 
Science International, 282, 41-45. doi:10.1016/j.forsciint.2017.10.023 
 
Bailey, C. A., Carlton, C. D., White, S. W. (2019). A Call to Policy Change: Cannabis 
in the NFL. Manuscript submitted for publication. 
 




Sigma Xi - How distance affects the microanatomy of gunshot wounds to the skull 




Sam Houston State University, Texas Research Institute for Environmental Studies 
  Student Assistant to Museum Curator, Dr. William Godwin 
  June 2019 – September 2019 
   
Sam Houston State University, Department of Biological Sciences 
  Secretary to the Department Chair, Dr. Tamara Cook 
  September 2018 – December 2018 
 
Sam Houston State University, Department of Biological Sciences 
  Lab Instructor – Botany 
  August 2017 – May 2018 
 
Sam Houston State University, Department of Biological Sciences 
  Lab Instructor – Foundations of Sciences 




BIOL 1411 – General Botany Lab, August 2017 - May 2018 
 




Global Medical Training, Arraijan District, Panama 
 Doctor’s Assistant 
 June 2015 
 
Shands Hospital, University of Florida, Gainesville, Florida 
 Physician Shadowed: Vincent Bird, MD 
 May – August 2014 
     
COMMUNITY OUTREACH 
 
President, Biological Sciences Graduate Student Organization, SHSU 
 Huntsville, TX 
Leader and head representative for all graduate students in the Department of  
Biological Sciences 
May 2018 - Present 
 
Webmaster, Biological Sciences Graduate Student Organization, SHSU 
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  Huntsville, TX 
Maintained clear communication between members, officers, faculty and the 
community 
January - May 2018 
 
Adaptive Golf Program Founder, Shriners Hospital for Children 
 Tampa, Florida       
Organized and designed various teaching activities for three annual events 
May 2009 – May 2016 
  
Internet and Social Media Relations, Community Health Service Corp.         
  Gainesville, FL 
Managed all community outreach via social media for organization operations 
August – December 2015 
   
Dream Team Monthly Volunteer, Shands Hospital 
  Gainesville, Florida           
Volunteered to spend time with children in the Cardiology department 
January 2014 – April 2014 
 
AWARDS & AFFILIATIONS 
 
Deliberative Dialogue Competition – 2nd Place 
 Sam Houston State University, Fall 2019 
 
College of Science and Engineering Technology (COSET) Graduate Achievement 
Scholarship 
 Sam Houston State University, Fall 2019 
 
College of Science and Engineering Technology (COSET) Graduate Achievement 
Scholarship 
 Sam Houston State University, Spring 2019 
 
Deliberative Dialogue Competition – 1st Place 
 Sam Houston State University, Fall 2018 
 
